Stage III NSCLC: Trimodality Therapy and Concurrent Chemoradiation

Stage III is a heterogeneous group

Stage III NSCLC spans tumors that are locally advanced but not metastatic — from operable single-station node disease to bulky multistation involvement. The right plan depends on exact T and N extent and whether surgery is feasible.

The role of concurrent chemoradiation

For unresectable stage III, concurrent chemotherapy and radiation is the backbone of treatment. Giving both at the same time (concurrent) outperforms sequencing them for local control.

Trimodality and consolidation

• Trimodality (chemotherapy plus radiation plus surgery) is considered when downstaging might convert an unresectable tumor to operable.
• Consolidation immunotherapy after chemoradiation in unresectable stage III has become standard to extend control.

A multidisciplinary tumor board helps weigh operability, nodal burden, and sequencing before committing to a path.